Interestingly, when DC101, an antimouse VEGFR2 antibody, was administered to a human HCC patient-derived xenograft mouse model, we observed not only an inhibition of mouse ECs but also a reduction in human AFP-positive HCC cells. Here, AFP is linked to hepatocellular carcinoma.